By designing an IL-1β-neutralizing antibody, this group demonstrated that intravenous administration of the anti-IL-1β antibody was able to preserve BBB integrity following experimental stroke, although the exact mechanisms of this change were not identified. The gene discussed is IL1B; the disease is Stroke.